ATE400296T1 - Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung - Google Patents

Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung

Info

Publication number
ATE400296T1
ATE400296T1 AT00992589T AT00992589T ATE400296T1 AT E400296 T1 ATE400296 T1 AT E400296T1 AT 00992589 T AT00992589 T AT 00992589T AT 00992589 T AT00992589 T AT 00992589T AT E400296 T1 ATE400296 T1 AT E400296T1
Authority
AT
Austria
Prior art keywords
biological molecules
compositions
methods
lyophilization
stabilizing biological
Prior art date
Application number
AT00992589T
Other languages
English (en)
Inventor
Irina Esikova
Sidney Wolfe
James Thomson
Hora Maninder
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22611688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE400296(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE400296T1 publication Critical patent/ATE400296T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT00992589T 1999-12-02 2000-12-01 Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung ATE400296T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16848699P 1999-12-02 1999-12-02

Publications (1)

Publication Number Publication Date
ATE400296T1 true ATE400296T1 (de) 2008-07-15

Family

ID=22611688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992589T ATE400296T1 (de) 1999-12-02 2000-12-01 Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung

Country Status (10)

Country Link
EP (2) EP1233784B1 (de)
JP (2) JP4948731B2 (de)
AT (1) ATE400296T1 (de)
CA (1) CA2393298C (de)
CY (1) CY1108382T1 (de)
DE (1) DE60039450D1 (de)
DK (1) DK1233784T3 (de)
ES (1) ES2307553T3 (de)
PT (1) PT1233784E (de)
WO (1) WO2001041800A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307553T3 (es) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.
ES2388848T3 (es) 2001-01-23 2012-10-19 Sanofi Pasteur Inc. Vacuna meningocócica polivalente preparada con un conjugado de polisacárido y proteína
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
MY132859A (en) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
JP2007501224A (ja) * 2003-08-05 2007-01-25 フジ フォト フィルム ビー．ブイ． 安定剤としての組換え又は合成ゼラチン様タンパク質の、凍結乾燥医薬組成物中の使用
US7883709B2 (en) 2003-10-23 2011-02-08 Novartis Ag Stabilised compositions
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP1896062B1 (de) 2005-06-27 2010-03-31 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
US10543265B2 (en) 2006-03-22 2020-01-28 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW201009337A (en) * 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
AR073997A1 (es) * 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
PL2608805T3 (pl) 2010-08-23 2017-12-29 Wyeth Llc Trwałe preparaty antygenów rLP2086 Neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
AU2012265320B2 (en) 2011-06-01 2016-11-03 Xiamen Innovax Biotech Co. Ltd. Fusion protein comprising diphtheria toxin non-toxic mutant CMR197 or fragment thereof
EP2793939A1 (de) * 2011-12-23 2014-10-29 Novartis AG Stabile zusammensetzungen zur immunisierung gegen staphylococcus aureus
US9283270B2 (en) 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2854822B1 (de) * 2012-05-30 2020-07-22 The Brigham and Women's Hospital, Inc. Polysaccharidzusammensetzungen und verfahren zur verwendung
US20140099380A1 (en) * 2012-06-28 2014-04-10 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
JP6266631B2 (ja) 2012-10-03 2018-01-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (de) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
EP3577130A2 (de) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
MX2021005303A (es) 2018-11-06 2021-07-07 Glaxosmithkline Biologicals Sa Composiciones inmunogenicas.
GB202208089D0 (en) * 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
EP1516628B1 (de) * 1995-07-27 2013-08-21 Genentech, Inc. Stabile isotonische lyophilisierte Proteinzusammensetzung
ES2307553T3 (es) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.

Also Published As

Publication number Publication date
JP2011137047A (ja) 2011-07-14
EP1233784A2 (de) 2002-08-28
ES2307553T3 (es) 2008-12-01
PT1233784E (pt) 2008-11-03
EP2292263A2 (de) 2011-03-09
CA2393298A1 (en) 2001-06-14
WO2001041800A2 (en) 2001-06-14
JP4948731B2 (ja) 2012-06-06
CY1108382T1 (el) 2014-02-12
WO2001041800A3 (en) 2002-01-03
JP2003516361A (ja) 2003-05-13
EP2292263A3 (de) 2011-07-27
DE60039450D1 (de) 2008-08-21
DK1233784T3 (da) 2008-09-01
EP1233784B1 (de) 2008-07-09
CA2393298C (en) 2011-02-01
WO2001041800A9 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
ATE400296T1 (de) Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
DE69433530D1 (de) Bmp-11 zusammensetzungen
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
DK0429570T3 (da) Osteoinducerende præparater
NO20025450D0 (no) Ny farmasöytisk sammensetning
DE69528058D1 (de) Bmp-9 zusammensetzungen
PT1041072E (pt) Acidos dioxociclopentil hidroxamicos
ATE265529T1 (de) Bmp-10 zusammensetzungen
BR0210282A (pt) Veìculos de distribuição de fosfato de cálcio para proteìnas osteoindutivas
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
ID25478A (id) Agonis 5-ht1f
DE60020729D1 (de) Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1233784

Country of ref document: EP